North Carolina macular dystrophy (MCDR1) caused by a novel tandem duplication of the PRDM13 gene by Bowne, Sara J et al.




North Carolina macular dystrophy (MCDR1)
caused by a novel tandem duplication of the
PRDM13 gene
Sara J. Bowne
University of Texas Health Science Center at Houston
Lori S. Sullivan
University of Texas Health Science Center at Houston
Dianna K. Wheaton
Retina Foundation of the Southwest
Kirsten G. Locke
Retina Foundation of the Southwest
Kaylie D. Jones
Retina Foundation of the Southwest
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Bowne, Sara J.; Sullivan, Lori S.; Wheaton, Dianna K.; Locke, Kirsten G.; Jones, Kaylie D.; Koboldt, Daniel C.; Fulton, Robert S.;
Wilson, Richard K.; Blanton, Susan H.; Birch, David G.; and Daiger, Stephen P., ,"North Carolina macular dystrophy (MCDR1)
caused by a novel tandem duplication of the PRDM13 gene." Molecular Vision.22,. 1239-1247. (2016).
http://digitalcommons.wustl.edu/open_access_pubs/5379
Authors
Sara J. Bowne, Lori S. Sullivan, Dianna K. Wheaton, Kirsten G. Locke, Kaylie D. Jones, Daniel C. Koboldt,
Robert S. Fulton, Richard K. Wilson, Susan H. Blanton, David G. Birch, and Stephen P. Daiger
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/5379
Families with North Carolina macular dystrophy were 
first identified more than 50 years ago [1]. Families initially 
were described with various terms for macular dystrophy 
and were linked only when genealogy showed a connection 
between them. Because the putative founder effect originated 
in North Carolina, the disease was named North Carolina 
macular dystrophy (NCMD) [2-4]. The mapping of NCMD 
in 1992 to chromosome 6q13-q16, called the MCDR1 locus, 
led the way for many more families with NCMD to be identi-
fied via linkage analysis [5-8]. Affected members of many of 
these families shared a common haplotype on chromosome 
6q supporting the concept of a founder mutation.
NCMD is an autosomal dominant form of non-progres-
sive macular impairment, originating during prenatal 
development with varying degrees of affectation or grades 
in adulthood [4,9]. Despite extensive studies over numerous 
years and by many scientists, no cause of disease has been 
found in the genes located in the chromosome 6 linkage 
region [10].
Recently, the cause of NCMD was identified using 
whole genome sequencing of individuals from two families 
mapped to the MCDR1 locus [9]. Sequence analysis identified 
a nucleotide substitution at chr6:100,040,906 G>T (hg19) that 
was subsequently found in nine families. In addition, a C>T 
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Purpose: To identify the underlying cause of disease in a large family with North Carolina macular dystrophy (NCMD).
Methods: A large four-generation family (RFS355) with an autosomal dominant form of NCMD was ascertained. Family 
members underwent comprehensive visual function evaluations. Blood or saliva from six affected family members and 
three unaffected spouses was collected and DNA tested for linkage to the MCDR1 locus on chromosome 6q12. Three 
affected family members and two unaffected spouses underwent whole exome sequencing (WES) and subsequently, 
custom capture of the linkage region followed by next-generation sequencing (NGS). Standard PCR and dideoxy se-
quencing were used to further characterize the mutation.
Results: Of the 12 eyes examined in six affected individuals, all but two had Gass grade 3 macular degeneration 
features. Large central excavation of the retinal and choroid layers, referred to as a macular caldera, was seen in an age-
independent manner in the grade 3 eyes. The calderas are unique to affected individuals with MCDR1. Genome-wide 
linkage mapping and haplotype analysis of markers from the chromosome 6q region were consistent with linkage to the 
MCDR1 locus. Whole exome sequencing and custom-capture NGS failed to reveal any rare coding variants segregating 
with the phenotype. Analysis of the custom-capture NGS sequencing data for copy number variants uncovered a tan-
dem duplication of approximately 60 kb on chromosome 6q. This region contains two genes, CCNC and PRDM13. The 
duplication creates a partial copy of CCNC and a complete copy of PRDM13. The duplication was found in all affected 
members of the family and is not present in any unaffected members. The duplication was not seen in 200 ethnically 
matched normal chromosomes.
Conclusions: The cause of disease in the original family with MCDR1 and several others has been recently reported 
to be dysregulation of the PRDM13 gene, caused by either single base substitutions in a DNase 1 hypersensitive site 
upstream of the CCNC and PRDM13 genes or a tandem duplication of the PRDM13 gene. The duplication found in the 
RFS355 family is distinct from the previously reported duplication and provides additional support that dysregulation 
of PRDM13, not CCNC, is the cause of NCMD mapped to the MCDR1 locus.
Correspondence to: Sara J. Bowne, PO Box 20186, Houston, 
TX; 77225; Phone: (713) 500 9836; FAX: (713) 500 0900; email: 
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substitution at chr6:100,041,040 was found in an additional 
family with NCMD. These two nucleotide substitutions are 
located in a DNase I hypersensitive site 5′ of two genes, PR/
SET domain-containing zinc finger protein 13 (PRDM13; 
Gene ID 59336, OMIM 616741) and cyclin-C protein (CCNC; 
Gene ID 892, OMIM 123838). In addition to these two nucle-
otide substitutions, a third family was found to have a 123 kb 
duplication of a region that includes the PRDM13 gene and 
the DNase I hypersensitive site. Experiments using induced 
pluripotent stem cells (iPSCs) suggested that the disease was 
likely due to the dysregulation of PRDM13 [9].
This study describes the clinical characterization and 
mutation identification of another NCMD family, RFS355, 
which maps to the MCDR1 locus. The tandem duplication 
identified in this family is different from that reported by 
Small et al., further strengthening the premise that dysregula-
tion of the PRDM13 gene, not the CCNC gene, is the cause of 
NCMD (MCDR1) [9].
METHODS
This study adhered to the Declaration of Helsinki and was 
approved by the Institutional Review Board at each partici-
pating institution. Written informed consent was obtained 
from each participant before the examination and genetic 
studies were performed.
Clinical characterization: Affected family members (n = 6) 
spanning three generations underwent ophthalmic exams that 
included visual acuity, retinal imaging, and fundus grading 
(Figure 1 and Figure 2)
Visual acuity: Electronic visual acuity (EVA) was measured 
with a computerized version of the electronic Early Treat-
ment Diabetic Retinopathy Study (E-ETDRS), which has 
been described previously [11]. Briefly, single high-contrast 
black letters are randomly displayed on a computer screen 
surrounded by crowding bars spaced a letter width around the 
letter. At the 3 m test distance, the letters are displayed from 
20/800 (1.6 LogMAR) to 20/12 (−0.2 LogMAR).
Retinal imaging: Frequency domain optical coherence tomog-
raphy (fdOCT) retinal imaging, including line and volume 
scans, was performed (Spectralis HRA+OCT, Heidelberg 
Engineering, Heidelberg, Germany). The fdOCT measure-
ments included the height, width, and depth of the macular 
calderas and the width of the papillomacular area, from the 
temporal edge of the disk to the nasal border of the caldera.
Color fundus photography used a 60 degree digital 
fundus camera (CF-60UD, Canon, Melville, NY, with 
Sonomed Escalon image capture software) to capture macula 
and optic nerve images of both eyes from most subjects. 
Three subjects also underwent autofluorescence imaging of 
the macula.
Fundus grading: The retinal lesion of each patient was char-
acterized as Gass grade 1, 2, or 3 based on the fundus exami-
nation and the color fundus photographs (Table 1) [12,13]. 
Varying degrees of drusen-like deposits were also noted. The 
clinical features of each Gass grade are as follows:
Grade 1: Limited to small (<50 μm) yellow drusen in the 
macula with possible mild RPE disturbances. Patients have 
visual acuity of 20/30 or better.
Grade 2: Larger elevated confluent yellow drusen with 
RPE atrophy and/or disciform scars with pigment clumping. 
Patients typically have visual acuity in the range from 20/25 
to 20/60, although old disciform scars from choroidal neovas-
cularization may lead to acuity in the 20/100 to 20/400 range.
Grade 3: Large central atrophic excavation of the retina 
and choroid referred to as a macular caldera. Patients have 
visual acuity in the range from 20/40 to 20/200.
Linkage analysis: DNA was extracted from peripheral blood 
and saliva using standard protocols [14]. Peripheral blood was 
collected by venipuncture into vacutainer tubes containing 
EDTA. Whole blood was stored at room temperature or buffy 
coats were stored at -80 °C. DNA was extracted using the 
Gentra Puregene Blood Kit (Qiagen, Valencia, CA) and the 
manufacture’s protocol with slight modifications as described 
previously [14]. Saliva was collected in Oragene DISCOVER 
(OGR-500) tubes from DNA Genotek (Ottawa, Canada) and 
stored at room temperature until DNA extraction could be 
performed. The collection tubes containing saliva were incu-
bated at 50° C and DNA extracted using the manufacture’s 
protocol with slight modifications as described previously 
[14]. DNAs from six affected individuals and three unaf-
fected spouses were genotyped at the Hussman Institute for 
Human Genomics Center for Genome Technology using the 
Affymetrix Genome-Wide Human SNP Array 6.0 (Santa 
Clara, CA). Processing and analysis were performed as previ-
ously described [15]. Briefly, DNA was digested with NspI 
and StyI restriction enzymes (New England Biolabs, Ipswich, 
MA), ligated to adapters and amplified using adapter-specific 
primers. PCR products were fragmented, labeled and loaded 
on the SNP 6.0 arrays. Hybridization was performed in a 
GeneChip Hybridization Oven (Affymetrix, Santa Clara, 
CA). Arrays were washed and stained with streptavidin 
phycoerythrin and scanned on a GeneChip Scanner 3000 7G 
(Affymetrix).
Single nucleotide polymorphism (SNP) genotype calls 
and copy number variation (CNV) analysis was performed 
on the raw Affymetrix Genome-Wide Human SNP 6.0 array 
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data using Genotyping Console™ (Affymetrix). PLINK was 
used for quality control and assessment [16]. Heterozygosity 
and inter-SNP distance were used to select a subset of SNPs 
for linkage analysis. All chosen SNPs were at least 0.2 cM 
apart and had average heterozygosity of 0.5. Centre d’Etude 
du Polymorphisme Humain (CEPH) Caucasian (CEU) data 
set allele frequencies were used for all calculations [17]. 
MERLIN was used to perform multipoint linkage analysis 
using a dominant model with 90% penetrance in heterozy-
gotes and disease allele frequency of 0.0001 [18,19].
Additional haplotype analysis was performed using short 
tandem repeat (STR) markers D6S1610, D6S300, D6S1671, 
and D6S434. Fluorescently labeled primers for amplifying 
the STRs were obtained from Applied Biosystems (Carlsbad, 
CA). Genomic DNA from all available family members 
was amplified and separated on a 3500xL DNA Sequencer 
(Applied Biosystems). STR alleles were determined using 
GeneMapper V3.7 (Applied Biosystems).
Genomic paired-end library construction: Genomic DNA (1 
μg) was used to make Illumina paired-end libraries according 
to the manufacturer’s protocol (Illumina Inc., San Diego, 
CA), with slight modifications as described previously [15].
Exome capture next-generation sequencing: Exome capture 
was performed using a Nimblegen SeqCap EZ Human 
Figure 1. RFS355 pedigree and duplication typing. A: Pedigree of NCMD family RFS355. Circles indicate female individuals while squares 
indicate male individuals. Diagonal lines indicate a deceased individual. Filled symbols indicate affected individuals while unfilled symbols 
indicate unaffected individuals. Individual ID numbers are located below the symbols. B: PCR product analysis of the presence or absence 
of the 69 kb duplication. PCR products of the three amplimers were combined and separated on an agarose gel. Results from each family 
member are in the lane directly underneath their symbol in the pedigree. The presence of the bottom band (shown by the arrow) indicates 
these individuals have the duplication on chromosome 6q.
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Exome Library v2.0 (Roche, Madison, WI) according to the 
manufacturer’s protocol. Illumina paired-end sequencing 
(2×100 bp), alignment, and variant calling were performed as 
described previously [20].
Targeted capture next-generation sequencing:
Custom capture and next-generation sequencing—A 
custom library was designed to capture genomic DNA found 
in the published MCDR1 locus. This custom library targeted 
all non-repetitive coding and non-coding DNA on chromo-
some 6 from 81,907,766–101,730,611 bp (hg19) [4,7,10,21,22]. 
Genomic libraries were hybridized with the MCDR1 capture 
library according to the manufacturer’s protocol [14]. The 
KAPA SYBR FAST qPCR Kit (KAPA Biosystems, Woburn, 
MA) was used for library quantification to determine the 
amount required to generate 180,000 clusters on a single 
lane of the Illumina GAIIx platform. Three lanes of 2×100 bp 
paired-end sequence were generated for each patient library 
using the SBS Sequencing Kit Ver. Three (Illumina).
Alignment and variant identification—Illumina reads 
were mapped to the human reference sequence (GRCh7-lite) 
using BWA v0.5.9 with parameters -t 4 -q 5; duplicates were 
Figure 2. FdOCT. Each figure represents a b-scan through the macula from either a 9 mm line or volume scan. The scans consist of 100 or 
15+ averaged scans taken with autoretinal tracking. The location of each scan is shown in the infrared image (bold green line). A: Grade 1 
eye in 9395. B: Grade 2 eye in 8688. C: Grade 3 eyes in 9395, 8602, and 8686, respectively.
Table 1. SummarizaTion of phySical examS performed.


















































































See Figure 1 for patient ID’s. N/A-data not available. *The +indicates an approximate measurement as both edges and bottom of caldera 
could not be visualized at same time. **Distance measure on fundus color image as no OCT scan was available of the papillo-macular 
bundle areas.
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marked using Picard v1.46. Reads with a mapping quality 
of zero, or that were marked as duplicates by Picard, were 
excluded from further analysis.
Putative SNPs and indels were called in the exome data 
using VarScan 2 and the following thresholds: coverage ≥8X, 
phred base quality ≥15, minimum variant allele frequency 
≥10%, and Fisher Exact Test p value <0.05 [23]. False posi-
tives were removed from paralogous alignments, local 
misalignments, sequencing errors, and other factors by 
filtering the SNVs to remove any with strand bias, read posi-
tion bias, or multiple high-quality mismatches in supporting 
reads. Predicted indels were filtered to remove small events 
around homopolymers, which likely are false positives.
Copy number analysis—On average, a 181X depth was 
achieved for affected individuals and a 185X depth for unaf-
fected individuals across the approximate 19.8 Mbp region 
of interest on chromosome 6. To search for copy number 
changes, the region of interest was divided into non-overlap-
ping 100-bp segments and average read depth for affected 
(n = 3) and unaffected (n = 2) individuals were computed 
according to SAMtools (r982) mpileup. The magnitude and 
direction of the copy number change were computed as log2 
(affected_depth/unaffected_depth). The resulting log2 values 
were segmented using the “DNAcopy” package in R with 
smoothing (data.type=“logratio,” undo.SD=4).
PCR confirmation and segregation analysis: PCR primers 
were designed to span the predicted CNV break points and 
the resulting junctions of the normal and duplicated genomic 
regions (Figure 3). PCR amplifications were performed using 
AmplitaqGold™ 360 Master Mix (Fisher, Waltham, MA) and 
the following amplification conditions: 95 °C 5 min; 95 °C 
1 min, 56 °C 1 min, 72 °C 1 min x35; 72 °C 5 min; 8 °C 
hold. Upon amplification, each PCR product was sequenced 
using standard dideoxy fluorescence Sanger sequencing and 
a 3500XL Genetic Analyzer (Applied Biosystems). Products 
were combined and run on agarose gels to confirm duplica-
tion segregation with disease (Figure 1). Primer sequences are 
available upon request.
RESULTS
Six affected members of the RFS355 family underwent 
comprehensive clinical exams. Clinical data are presented in 
Table 1. The six affected individuals were tested at several 
different ages spanning the first to sixth decades of life. Each 
individual had good to moderate visual acuity ranging from 
20/16 to 20/125. Technical details related to the acquisition 
of OCT in these patients have been reported previously [24].
A single eye of individual RFS355–9395 had a grade 1 
Gass score while a single eye of RFS355–8688 was grade 2 
(Figure 2). All the other eyes had grade 3 Gass phenotypes 
with varying size calderas, where the smallest were only half 
the size of the largest. Calderas were centered in the macula 
at the location of the missing fovea. In spite of the wide range 
of sizes, the distances between the disk and the nasal edge of 
the caldera were relatively similar, suggesting that the expan-
sion during caldera formation was primarily in the temporal 
direction. The preserved nasal retina typically contained the 
preferred locus of fixation, which probably explains the good 
vision in these patients. The size and depth of the calderas 
were not age dependent, as the youngest individual tested 
(RFS355–8687) had the largest lesion when compared to 
older family members.
Genome-wide linkage analysis was performed on all 
available affected and relevant unaffected family members 
(n = 9) using Affymetrix Genome-Wide Human SNP Array 
6.0 and MERLIN analyses. The majority of the genome had 
logarithm (base 10) of odds (LOD) scores of less than −2. A 
few genomic regions were also found to have LOD scores 
between −2 and 0. Only one region was found to have a 
LOD score above zero. This region on chromosome 6 had a 
maximum LOD score of 1.8. Chromosome 6q STR markers 
confirmed that a consistent haplotype existed in all affected 
family individuals and was not present in any unaffected 
individuals. The common haplotype was located on chromo-
some 6q14-16 in a region consistent with the reported North 
Carolina macular dystrophy locus, MCDR1 [25].
On the initial examination of the exome data, no poten-
tially deleterious point mutations or small indels within 
coding sequences of the genes in the linkage region were 
observed to segregate with disease in the family. To increase 
coverage and examine any possible copy number varia-
tions, a custom capture library was designed to capture as 
much of the MCDR1 locus as possible, including the coding 
sequences and introns and other non-coding, non-repetitive 
DNA sequences.
Analysis of the variants identified in the custom capture 
region yielded no new candidates. However, analysis of the 
data for the CNVs showed an increased copy number in a 
region of chromosome 6 indicating a duplication. In the 68.8 
Kbp region of duplication, the read depths were 1.5-fold 
higher in the affected individuals (283X for affected, 195X 
for unaffected, log2 ratio = 0.563; Figure 4).
When the duplication was detected, there was no 
convincing way to determine if or how this duplication was 
related to disease. Subsequently, the recent paper by Small 
et al. identified a duplication in another family with NCMD 
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Figure 3. Pictorial representation of the wild-type and pathogenic duplicated regions on chromosome 6. Green bars indicate the wild-type 
region on chromosome 6 while the yellow bars indicate the duplicated region. Red asterisks indicate the DNase I hypersensitivity site. Small 
arrows below the chromosome bar pictorials are the three pairs of PCR primers that produce different size products. The PCR product 
generated from these primers was used to determine the presence or absence of the deletion and the exact sequence of the duplication in 
family members (Figure 1B). Red and blue primers should amplify from the wild-type and duplicated chromosomes. The orange primers 
amplify only on the duplicated chromosome. Sequencing of the PCR product resulting from the orange depicted primers determined the 
exact duplication break point and the inclusion of 5 bp of exogenous DNA, TCCTG, between the wild-type and duplicated regions. Large 
horizontal black arrows with gene names above illustrate the strand and transcriptional direction of each gene. Vertical lines and blocks 
represent exons. The duplication found of the CCNC gene is only from exons 1 through 9 making it unlikely that any protein is generated 
from the duplicated region. The presence of the entire PRDM13 gene downstream from the DNase hypersensitivity site likely causes a change 
in PRDM13 protein levels compared to wild-type levels.
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at approximately the same region as the RFS355 family [9]. 
Given evidence that CNVs are a cause of NCMD, our data 
suggested the duplication identified in RFS355 could be a 
likely cause of disease in this family.
Based on the targeted capture CNV results, the genomic 
DNA duplication in the NCMD family is located from 
approximately 99,996,220–100,065,140 bp (hg19) on chro-
mosome 6q16.2 (Figure 3). To confirm the duplication and 
determine its exact size, two pairs of PCR primers were 
designed to flank the wild-type sites; the primers amplify 
the complete region in affected and unaffected individuals, 
regardless of whether the duplication is present or not. A third 
set of PCR primers was designed to flank the 6q telomeric 
region of the normal chromosome and the centromeric region 
of the duplicated 6q regions (Figure 3). PCR products from 
one affected and one unaffected individual were sequenced 
to determine the exact duplication locations and their rela-
tionship to canonical genomic DNA. These amplifications 
showed that the duplication segregated with disease in the 
RFS355 family. Sequencing of the PCR products determined 
the exact break points and the 5 bp of inserted, exogenous 
DNA sequence (Figure 1 and Figure 3)
DISCUSSION
We investigated a family with a retinal phenotype similar to 
that of other families with NCMD. Linkage analysis in this 
family mapped the disease locus to 6q14-16, which contains 
the MCDR1 locus. Targeted capture NGS and follow-up PCR-
based fluorescent sequencing determined that the cause of 
disease in this family lies within the MCDR1 locus region. 
The retinal disease in this family is caused by a 68,912 bp 
duplication which contains an entire intact PRDM13 gene 
copy, a partial CCNC gene copy, and a copy of the DNase I 
hypersensitive site located between the 5′ ends of both genes. 
The distinct mutation in this family with NCMD further 
demonstrates that multiple mutations are responsible for the 
NCMD phenotype.
Figure 4. CNV detection of chromosome 6q duplication. Copy number change in the CCNC-PRDM13 regions for affected individuals (n 
= 3) relative to unaffected individuals (n = 2), as computed by the log2 ratio of the read depth. Blue points represent the log2 ratio inferred 
from the mean depth in 100-bp bins. Red lines indicate the copy number segments inferred by the DNAcopy R package.
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As there is only a partial copy of the CCNC gene, it is 
probable that any mRNA generated undergoes nonsense-
mediated decay and no additional CCNC protein is produced, 
regardless of the presence of the extra DNase I hypersensitive 
site. The only gene in the duplication that is likely to make 
intact mRNA and protein is PRDM13. Further, it is likely that 
the duplication of the DNase I hypersensitive region affects 
the duplicated PRDM13 gene and may even affect the wild-
type PRDM13 gene.
PRDM proteins are tissue-specific transcription factors 
[26]. Research has shown that in induced pluripotent cells, 
PRDM13 mRNA levels decrease as stem cells become 
mature neural cells [9]. Recently, it was shown that Prdm13 is 
expressed in developing and mature mouse retinal amacrine 
cells. Prdm13−/− mouse retinas show a decreased number of 
amacrine cells in the inner nuclear layer and are thought to 
regulate amacrine subtype specification [27].
The duplicated copy of the PRDM13 gene and hyper-
sensitive DNase site found in RFS355 might lead to over-
expression of PRDM1, which may be the cause of NCMD 
symptoms, possibly through amacrine cell regulation in the 
neural retina. Results presented here further strengthen the 
argument presented by Small et al. that dysregulation of the 
PRDM13 gene is the cause of families with NCMD that map 
to the MCDR1 locus on chromosome 6q [9].
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